Typhoid is contagious disease caused by bacterial species, salmonella enterica and serovar typhi. It is also caused by salmonella paratyphi. A person is infected with typhoid on ingestion of water or food contaminated with stools of an individual infected with typhoid. Typhoid is also referred as typhoid fever, enteric fever, gastric fever, infantile remittent fever, abdominal typhus, nervous fever, and slow fever. Common symptoms of typhoid include, loss of appetite, lethargy, headache, diarrhea, body temperature elevated up to 104 degree Fahrenheit, presence of blood in stools, mood swings, bleeding nose, weakness, hallucinations, chills, agitation, and delirium. Diagnosis of the disease is done using complete blood count (CBC) test, blood culture, enzyme linked immunoassay (ELISA), stool culture, and platelet count tests. According to the World Health Organization (WHO), typhoid affects 16 million people worldwide every year and around 600,000 succumb to the disease globally.
Based on treatment, the global typhoid treatment market is segmented into medications and supportive therapy. Medications primarily include antibiotics such as chloramphenicol, ciprofloxacin, ceftriaxone, ampicillin, and trimethoprim-sulfamethoxazole. Supportive therapy includes intravenous (IV) fluids and intravenous electrolyte fluids. Typhoid is preventable through vaccines. The available vaccine in the typhoid treatment market are Ty21a and ViCPS. Rapidly rising morbidity rate and mortality rate of typhoid globally, increasing government initiative to control the number of typhoid cases in the country, rising health care awareness, affordable medication cost, and rapidly developing health care facilities are factors boosting the global typhoid treatment market. However, lack of early detection of typhoid and social stigma associated with the disease and its treatments especially in developing countries are factors restraining the global typhoid treatment market.
Geographically, the global typhoid treatment market is classified into five regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Currently, North America is dominating the global typhoid treatment market and is closely followed by Europe. High prevalence of typhoid, availability of highly advanced health care facilities, higher health care spending, availability of reimbursement policies, higher rate of awareness about typhoid and available treatments, and well-structured regulatory framework are some factors boosting the typhoid treatment market in North American and Europe.
The market in Asia Pacific is expected to expand at a rapid pace in the near future. Factors such as rapidly developing health care infrastructure, rising disposable income, availability of highly advanced health care facilities, increasing health care spending, and government initiatives to control mortality rate of typhoid in countries in Asia Pacific are factors fuelling the typhoid treatment market in Asia Pacific. India, China, and Japan are expected to have significantly higher growth potential in the Asia Pacific typhoid treatment market owing to the rapidly rising medical tourism industry in these countries. Despite having high mortality and morbidity rates of typhoid in countries in Africa, they are expected to show low growth rate owing to the poorly developed health care facilities in these countries; therefore, development of health care facilities in these countries, is likely to boost the typhoid treatment market at a slow pace in these countries. Major players operating in the global typhoid treatment market are GlaxoSmithKline, Bharat Biotech, Bayer, Sanofi S. A., and Pfizer.